[
    {
        "pregunta": "1. What are the key extraarticular conditions that may influence the management of juvenile idiopathic arthritis (JIA), according to the clinical guidelines?",
        "respuesta": "I don't have enough information to provide the key extraarticular conditions that may influence the management of juvenile idiopathic arthritis (JIA) according to the clinical guidelines.",
        "contexto": [
            "JIA guidelines, these recommendations are for persons already diagnosed as having JIA. 2. Aside from poor prognostic features specified within the recommendations themselves (e.g., specific joints for oligoarthritis, macrophage activation syndrome [MAS]), coexisting extraarticular conditions that would influence disease management, such as uveitis, psoriasis, or inflammatory bowel disease, are not addressed within these guidelines. 3. Recommendations are intended to be used by all clinicians",
            "guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making",
            "|There is no preferred biologic agent.| | | |\n|Consideration of poor prognostic features (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 19. In children with JIA with active TMJ arthritis, should poor prognostic features alter the treatment paradigm?|60|</p>",
            "|There is no preferred biologic DMARD.| | | |\n|Consideration of risk factors for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, and/or TMJ, presence of erosive disease or enthesitis, delay in diagnosis, elevated levels of inflammation markers, symmetric disease) is conditionally recommended to guide treatment decisions.|Very low|PICO 9. In children with oligoarticular JIA, should poor prognostic features alter the treatment paradigm?|51–52|",
            "values, goals, and preferences This guideline breaks new ground in recommending treatment withdrawal for children with systemic JIA, who may have lower risks of flare than are associated with other forms of JIA The low quality of evidence supporting these recommendations underscores the importance of clinical judgment and shared decision-making in everyday care of individuals with JIA. Similarly, this guideline and the many uncertainties acknowledged herein represent a powerful reminder of the"
        ]
    },
    {
        "pregunta": "2. Why is longer-term glucocorticoid therapy not appropriate in childhood for JIA patients?",
        "respuesta": "Longer-term glucocorticoid therapy in childhood is not appropriate for JIA patients due to its effects on bone health and growth. The guideline recommends limiting glucocorticoid therapy to the lowest effective dosage for the shortest duration possible to minimize these potential adverse effects. The goal is to achieve disease control while minimizing the risk of long-term complications associated with glucocorticoid use in children with juvenile idiopathic arthritis.",
        "contexto": [
            "they can have a rapid onset of action. However, although treatment with high-dose glucocorticoids may be required for disease control, subsequent glucocorticoid therapy should be limited to the lowest effective dosage for the shortest duration possible. Longer-term glucocorticoid therapy in children is not appropriate because of its effects on bone health and growth Systemic JIA with MAS: subsequent therapy (Table 6 Biologic DMARDS or csDMARDs are strongly recommended over long-term",
            "guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making",
            "|Oral glucocorticoids are conditionally recommended against as part of initial therapy.|Very low|PICO 13. In children with JIA with active TMJ arthritis, should adding oral glucocorticoids to initial therapy be recommended?|58|",
            "6 Biologic DMARDS or csDMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. Inactive systemic JIA with or without history of MAS (Table 7 Tapering and discontinuing glucocorticoids is strongly recommended after inactive disease has been attained in systemic JIA. The risk of flare from systemic JIA that is well controlled is considerably outweighed by possible harms from long-term glucocorticoid use, even at",
            "proportion of patients with systemic JIA will respond to NSAIDs alone Glucocorticoids Oral glucocorticoids are conditionally recommended against as initial monotherapy for systemic JIA without MAS. In most cases, oral glucocorticoids should not be used as initial monotherapy in patients with systemic JIA without MAS and, if used, should be limited to the lowest effective dosage for the shortest duration possible. This recommendation is conditional, as bDMARDs may not always be immediately"
        ]
    },
    {
        "pregunta": "3. What is the recommended approach for shared decision-making when considering treatment options for JIA?",
        "respuesta": "The recommended approach for shared decision-making in considering treatment options for JIA according to the clinical guidelines emphasizes the importance of engaging in shared decision-making with families and patients when considering treatment options. The guideline highlights the need to involve patients and their families in the decision-making process to consider their values, goals, and preferences. This approach aims to ensure that the treatment decisions made are aligned with the individual needs and preferences of the patient with JIA.",
        "contexto": [
            "guidelines. 3. Recommendations are intended to be used by all clinicians caring for persons with JIA and assume that patients do not have contraindications to the recommended pharmacologic treatments. 4. Longer-term glucocorticoid therapy in childhood is not appropriate because of its effects on bone health and growth. Thus, wherever glucocorticoids are suggested, recommended treatment should be limited to the lowest effective dose for the shortest duration possible. 5. Shared decision-making",
            "dose for the shortest duration possible. 5. Shared decision-making with families and patients is important when considering treatment options. RESULTS/RECOMMENDATIONS The initial literature review included topics addressed in this report and in the second report https://onlinelibrary.wiley.com/doi/10.1002/ 2 3 4 5 6 7 3 4 5 6 7 Active oligoarthritis (Figure 1 3 Oligoarthritis refers to JIA presenting with involvement of ≤4 joints without systemic manifestations. It may include patients with",
            "values, goals, and preferences This guideline breaks new ground in recommending treatment withdrawal for children with systemic JIA, who may have lower risks of flare than are associated with other forms of JIA The low quality of evidence supporting these recommendations underscores the importance of clinical judgment and shared decision-making in everyday care of individuals with JIA. Similarly, this guideline and the many uncertainties acknowledged herein represent a powerful reminder of the",
            "recommendations indicate that clinicians should engage in shared decision-making with patients when deciding whether to use these interventions. The low or very low certainty evidence supporting most recommendations calls for prioritizing research into these interventions and prompted a proposed research agenda (Table 7 There are limitations to the development of these guidelines. Studies that were conducted prior to more recent treatment eras (characterized by early diagnosis of RA and a",
            "context of shared decision-making with patients, to choose the safest and most effective treatment possible. A large research agenda remains to be addressed, with a need for more options with greater efficacy for the millions of people worldwide with osteoarthritis. Addendum. Therapies that were approved after the original systematic literature review are not included in these recommendations.   1 Sharon L. Kolasinski, MD FACP FACR Joel Block Rush University Medical Center, Chicago, Illinois 7"
        ]
    },
    {
        "pregunta": "4. What is the role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the initial therapy for active oligoarthritis in JIA?",
        "respuesta": "Nonsteroidal anti-inflammatory drugs (NSAIDs) are conditionally recommended as part of the initial therapy for active oligoarthritis in juvenile idiopathic arthritis (JIA) according to the clinical guidelines. NSAIDs have long been considered the cornerstone of treatment for oligoarthritis and can help ease discomfort. However, the initial trial of NSAIDs should be brief due to potential adverse effects like gastritis and bruising, as well as limited efficacy unless inactive disease is achieved. The appropriate duration of initial NSAID use before escalating therapy is not clearly defined in the guidelines.",
        "contexto": [
            "of ≤4 joints without systemic manifestations. It may include patients with different categories of JIA  but who share in common limited numbers of joints involved; guidance for patients with active uveitis, sacroiliitis, or enthesitis can be found in the 2019 guidelines Nonsteroidal antiinflammatory drugs (NSAIDs) A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy for active oligoarthritis. NSAIDs have long been the cornerstone of treatment for oligoarthritis",
            "NSAIDs have long been the cornerstone of treatment for oligoarthritis and can ease discomfort . However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and limited efficacy (unless inactive disease is achieved). Voting panelists could not agree on the appropriate duration of initial use before escalating therapy, as some panelists prefer that the use of NSAIDs be avoided altogether. Glucocorticoids Intraarticular glucocorticoids (IAGCs) are",
            "are several validated disease activity measures for childhood arthritis Treat-to-target approaches have been strongly endorsed for polyarticular JIA Active TMJ arthritis (Figure 2 4 NSAIDs A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy for active TMJ arthritis. NSAIDs have long been the cornerstone of treatment for JIA and can ease discomfort . However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and",
            "<p>|Recommendation|Certainty of evidence|PICO evidence report(s) basis|Page no(s).|\n|---|---|---|---|\n|NSAIDs are conditionally recommended as initial monotherapy.|Very low|PICO 20. In patients with treatment-naive, newly diagnosed systemic JIA without MAS, should non-DMARD treatment (NSAIDs, glucocorticoids) be used as initial therapy?|61–67|\n|Oral glucocorticoids are conditionally recommended against as initial monotherapy.| | | |",
            "In our defined population, we conditionally recommend proceeding to TJA without delay over delaying surgical treatment for a trial of NSAIDs. The NSAIDs are one of the mainstays of nonoperative treatment for OA and can provide pain relief for patients with mild disease. Oral NSAIDs are, however, associated with adverse events (e.g., peptic ulcer disease, acute kidney injury, increased cardiovascular risk, and bleeding) In our defined population, we conditionally recommend proceeding to TJA"
        ]
    },
    {
        "pregunta": "5. Why are intraarticular glucocorticoids strongly recommended as part of initial therapy for active oligoarthritis in JIA?",
        "respuesta": "Intraarticular glucocorticoids are strongly recommended as part of initial therapy for active oligoarthritis in JIA due to their low potential for adverse effects and high likelihood of sustained response. The evidence supporting the use of intraarticular glucocorticoids in this context is of low quality. Additionally, there is no preferred agent for intraarticular glucocorticoid injections in patients with JIA.",
        "contexto": [
            "altogether. Glucocorticoids Intraarticular glucocorticoids (IAGCs) are strongly recommended as part of initial therapy for active oligoarthritis. Triamcinolone hexacetonide is strongly recommended as the preferred agent. Although the evidence is of low quality, IAGCs are strongly recommended due to low potential of adverse effects and high likelihood of sustained response Oral glucocorticoids are conditionally recommended against as part of initial therapy for active oligoarthritis. If, despite",
            "the relative merits of different NSAIDs, there is evidence suggesting that certain agents may have more favorable side effect profiles than others Intraarticular glucocorticoid injections are strongly recommended for patients with knee and/or hip OA and conditionally recommended for patients with hand OA. Trials of intraarticular glucocorticoid injections have demonstrated short-term efficacy in knee OA. Intraarticular glucocorticoid injection is conditionally, rather than strongly, recommended",
            "|IAGCs are conditionally recommended as part of initial therapy.|Very low|PICO 12. In children with JIA with active TMJ arthritis, should adding intraarticular glucocorticoids to initial therapy be recommended?|53–57|\n|There is no preferred agent.|Very low|PICO 14. In children with JIA with active TMJ arthritis, should a specific steroid type be recommended for intraarticular injection?|58|",
            "|Oral glucocorticoids are conditionally recommended against as part of initial therapy.|Very low|PICO 13. In children with JIA with active TMJ arthritis, should adding oral glucocorticoids to initial therapy be recommended?|58|",
            "NSAIDs have long been the cornerstone of treatment for oligoarthritis and can ease discomfort . However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and limited efficacy (unless inactive disease is achieved). Voting panelists could not agree on the appropriate duration of initial use before escalating therapy, as some panelists prefer that the use of NSAIDs be avoided altogether. Glucocorticoids Intraarticular glucocorticoids (IAGCs) are"
        ]
    },
    {
        "pregunta": "6. Which conventional synthetic DMARD is conditionally recommended as a preferred agent for JIA patients with inadequate response to NSAIDs and/or intraarticular glucocorticoids?",
        "respuesta": "I don't have enough information to provide the specific conventional synthetic DMARD that is conditionally recommended as a preferred agent for JIA patients with inadequate response to NSAIDs and/or intraarticular glucocorticoids according to the clinical guidelines.",
        "contexto": [
            "recommendation is conditional, as bDMARDs may not always be immediately available, and glucocorticoids may help control systemic and joint manifestations until IL-1 or IL-6 inhibitors can be started. Conventional synthetic DMARDs Conventional synthetic DMARDs are strongly recommended against as initial monotherapy for systemic JIA without MAS. This recommendation is strong despite limited evidence, as the Voting Panel noted multiple small studies of systemic JIA that documented lack of efficacy",
            "|There is no preferred agent.| | | |\n|IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of conventional synthetic DMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids.|Very low|PICO 23. In patients with systemic JIA without MAS who do not respond to initial therapy with nonbiologic treatments (NSAIDs, glucocorticoids, DMARDs), should nonbiologic treatments be combined or biologic treatment started?|72–130|",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. There is no preferred agent.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or",
            "for systemic JIA without MAS. Most physicians and patients/caregivers preferred quickly starting IL-1 or IL-6 inhibitors for insufficient response to NSAIDs or glucocorticoids Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. There is no preferred agent. Given the potential toxicities from long-term use of glucocorticoids Systemic JIA with MAS: initial therapy",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or"
        ]
    },
    {
        "pregunta": "7. What is the rationale behind the preference for subcutaneous over oral administration of methotrexate in JIA patients with polyarticular arthritis?",
        "respuesta": "The rationale for preferring subcutaneous over oral administration of methotrexate in JIA patients with polyarticular arthritis is based on the 2019 JIA guidelines, which conditionally recommended subcutaneous administration over oral administration for polyarthritis. This recommendation was made due to the very low quality of evidence supporting the route of administration, and the consideration that patient preferences may influence the choice of route. The guidelines suggested that there is little reason to suggest that methotrexate should be used differently in oligoarthritis compared to polyarthritis.",
        "contexto": [
            "and efficacy in children With regard to the route of administration of methotrexate, the 2019 JIA guidelines conditionally recommended subcutaneous over oral administration for polyarthritis . This recommendation was conditional because the supporting evidence was of very low quality and patient preferences may guide choice of route of administration. There is little reason to suggest that methotrexate should be used differently in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs)",
            "or tsDMARD The recommendation is conditional because the voting panel thought that some patients who have already had persistent disease activity despite use of ≥1 csDMARD will prefer combination treatment for a more rapid response. Recommendations for administration of methotrexate (Table 3) Oral methotrexate is conditionally recommended over subcutaneous methotrexate for patients initiating methotrexate Oral administration is preferred, despite moderate evidence suggesting superior efficacy",
            "|Switching to subcutaneous methotrexate is conditionally recommended over the addition of/switching to alternative DMARD(s) for patients taking oral methotrexate who are not at target.|Very low|PICO 18|p. 235|</p>",
            "is preferred, despite moderate evidence suggesting superior efficacy of subcutaneous injections, due to the ease of oral administration and similar bioavailability at typical starting doses Initiation/titration of methotrexate to a weekly dose of at least 15 mg within 4 to 6 weeks is conditionally recommended over initiation/ titration to a weekly dose of <15 mg The recommendation is conditional because there are few studies comparing different dosing strategies and wide variation in physician",
            "24 hours or weekly subcutaneous injections, and/or an increased dose of folic/folinic acid, is conditionally recommended over switching to alternative DMARD(s) for patients not tolerating oral weekly methotrexate Despite the very low certainty of evidence supporting these strategies for alleviating side effects related to methotrexate, split dosing, changing to the subcutaneous route of administration, and increased doses of folic/folinic acid are the preferred initial strategies over switching"
        ]
    },
    {
        "pregunta": "8. When should biologic DMARDs be strongly recommended for JIA patients with inadequate response to NSAIDs and/or conventional synthetic DMARDs?",
        "respuesta": "Yes, based on the retrieved documents, biologic DMARDs are strongly recommended for JIA patients with inadequate response to NSAIDs and/or conventional synthetic DMARDs, specifically for active oligoarthritis. There is no preferred biologic DMARD recommended, but biologic DMARDs are preferred over combining conventional synthetic DMARDs or switching to a different conventional synthetic DMARD for patients with this condition.",
        "contexto": [
            "|Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 conventional synthetic DMARD.|Very low|PICO 6. In children with oligoarticular JIA, should biologic therapies be recommended, and should there be any preferred order of treatment: TNFi treatment, biologic treatments with other mechanisms of action?|42–47|\n|There is no preferred biologic DMARD.| | | |",
            "in oligoarthritis than in polyarthritis. Biologic DMARDs (bDMARDs) Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 csDMARD for active oligoarthritis. There is no preferred bDMARD. Biologic DMARDs are preferred over combining csDMARDs or switching to a different csDMARD, due to a greater likelihood that bDMARDs will yield rapid and sustained improvement in JIA Although tumor necrosis factor inhibitors (TNFi) are the",
            "|There is no preferred agent.| | | |\n|IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of conventional synthetic DMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids.|Very low|PICO 23. In patients with systemic JIA without MAS who do not respond to initial therapy with nonbiologic treatments (NSAIDs, glucocorticoids, DMARDs), should nonbiologic treatments be combined or biologic treatment started?|72–130|",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or abatacept or rituximab or IVIG or",
            "|Biologic DMARDs or conventional synthetic DMARDs are strongly recommended over long-term glucocorticoids for residual arthritis and incomplete response to IL-1 and/or IL-6 inhibitors. There is no preferred agent.|Very low|PICO 27. In patients with systemic JIA in whom inactive disease is not achieved despite treatment with both IL-1 and IL-6 agents and/or who are chronically steroid dependent, is long-term stable steroid treatment superior to nonsteroid treatments (cyclophosphamide or"
        ]
    },
    {
        "pregunta": "9. Why is formal assessment of disease activity using validated measures conditionally recommended for JIA patients?",
        "respuesta": "Formal assessment of disease activity using validated measures is conditionally recommended for JIA patients to guide treatment decisions, especially to facilitate treat-to-target approaches. This recommendation is based on the need to reach predefined treatment targets, consider the impact of specific joints or disease features, and take into account the number of remaining available treatment options. Additionally, patient factors such as noninflammatory causes of pain, comorbidities, and the patient's threshold for changing medications may influence the decision to follow a treat-to-target approach in this population.",
        "contexto": [
            "to guide treatment decisions. Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches. Treatment for oligoarthritis can and should be modified based on the involvement of specific joints or disease features Voting panelists conditionally recommended formal assessment of disease activity using validated measures. There are several validated disease activity measures for childhood arthritis",
            "|Use of validated disease activity measures is conditionally recommended to guide treatment decisions, especially to facilitate treat-to-target approaches.|Very low|PICO 10. In children with oligoarticular JIA, should disease activity measures alter the treatment paradigm?|52|</p>",
            "of disease activity using validated measures to reach a predefined target. Moreover, 1) the number of remaining available treatment options, 2) the impact of noninflammatory causes of pain, comorbidities, and/or damage on the accuracy of validated disease activity assessments, and 3) the patient's threshold for changing medications may have a more significant influence on the decision to follow a treat-to-target approach in this population compared to patients who are bDMARD-and tsDMARD-naive.",
            "JIA guidelines, these recommendations are for persons already diagnosed as having JIA. 2. Aside from poor prognostic features specified within the recommendations themselves (e.g., specific joints for oligoarthritis, macrophage activation syndrome [MAS]), coexisting extraarticular conditions that would influence disease management, such as uveitis, psoriasis, or inflammatory bowel disease, are not addressed within these guidelines. 3. Recommendations are intended to be used by all clinicians",
            "are several validated disease activity measures for childhood arthritis Treat-to-target approaches have been strongly endorsed for polyarticular JIA Active TMJ arthritis (Figure 2 4 NSAIDs A trial of scheduled NSAIDs is conditionally recommended as part of initial therapy for active TMJ arthritis. NSAIDs have long been the cornerstone of treatment for JIA and can ease discomfort . However, the initial NSAID trial should be brief due to potential adverse effects (e.g., gastritis, bruising) and"
        ]
    },
    {
        "pregunta": "10. What is the recommended initial therapy for systemic JIA without macrophage activation syndrome (MAS) according to the guidelines?",
        "respuesta": "The recommended initial therapy for systemic JIA without macrophage activation syndrome (MAS) according to the guidelines is the conditionally recommended use of biologic DMARDs, specifically IL-1 and IL-6 inhibitors, as initial monotherapy. There is no preferred agent specified, but IL-1 and IL-6 inhibitors are considered extremely effective and well-tolerated treatments for systemic JIA. It is noted that glucocorticoids are conditionally recommended against as initial monotherapy for systemic JIA without MAS, and conventional synthetic DMARDs are strongly recommended against as initial monotherapy for this condition.",
        "contexto": [
            "multiple small studies of systemic JIA that documented lack of efficacy at controlling systemic features that are typically present at onset of disease, leading to a continued need for glucocorticoids Systemic JIA without MAS: subsequent therapy (Table 5 IL-1 and IL-6 inhibitors are strongly recommended over a single or combination of csDMARDs for inadequate response to or intolerance of NSAIDs and/or glucocorticoids for systemic JIA without MAS. Most physicians and patients/caregivers",
            "bDMARD because current studies of TMJ arthritis have been small and observational Systemic JIA with and without MAS (Figure 3 Systemic JIA without MAS: initial therapy (Table 5) Biologic DMARDs Biologic DMARDS (IL-1 and IL-6 inhibitors) are conditionally recommended as initial monotherapy for systemic JIA without MAS. There is no preferred agent. IL-1 and IL-6 inhibitors are extremely effective and welltolerated treatments for systemic JIA  and have been rapidly adopted in clinical practice",
            "proportion of patients with systemic JIA will respond to NSAIDs alone Glucocorticoids Oral glucocorticoids are conditionally recommended against as initial monotherapy for systemic JIA without MAS. In most cases, oral glucocorticoids should not be used as initial monotherapy in patients with systemic JIA without MAS and, if used, should be limited to the lowest effective dosage for the shortest duration possible. This recommendation is conditional, as bDMARDs may not always be immediately",
            "JIA guidelines, these recommendations are for persons already diagnosed as having JIA. 2. Aside from poor prognostic features specified within the recommendations themselves (e.g., specific joints for oligoarthritis, macrophage activation syndrome [MAS]), coexisting extraarticular conditions that would influence disease management, such as uveitis, psoriasis, or inflammatory bowel disease, are not addressed within these guidelines. 3. Recommendations are intended to be used by all clinicians",
            "recommendation is conditional, as bDMARDs may not always be immediately available, and glucocorticoids may help control systemic and joint manifestations until IL-1 or IL-6 inhibitors can be started. Conventional synthetic DMARDs Conventional synthetic DMARDs are strongly recommended against as initial monotherapy for systemic JIA without MAS. This recommendation is strong despite limited evidence, as the Voting Panel noted multiple small studies of systemic JIA that documented lack of efficacy"
        ]
    }
]